1.Effect of ulinastatin on perioperative glycocalyx and lung function in patients undergoing mitral valve replacement surgery.
Qiang LÜ ; Deliang WANG ; Dongli XIE
Journal of Central South University(Medical Sciences) 2018;43(6):646-650
To explore the effect of ulinastatin on perioperative glycocalyx and lung function in patients undergoing mitral valve replacement surgery.
Methods: Fourty patients, undergoing mitral valve replacement, were randomly allocated into a control group and an ulinastatin group, which were administrated 50 mL normal saline or 2×104 U/kg ulinastatin at the beginning of cardiopulmonary bypass (CPB), respectively. The radical artery blood was collected at 4 time points: After induction of anesthesia (T0), at 10 min after the start of CPB (T1), 1 h after the end of CPB (T2), and 8 h after operation. The concentration of syndecan-1 and TNF-α in blood was measured. Moreover, the blood gas analysis was preformed and the oxygen index (OI) and difference in alveolar arterial oxygen partial pressure (PA-aO2) were calculated at T0, T2, and T3.
Results: There were no significant difference between the 2 groups in OI, PA-aO2, and the concentration of syndecan-1 and TNF-α at T0 (P>0.05). The concentration of syndecan-1 and TNF-α was significantly increased at T1 and T2 in the 2 groups, and reached peak at T2. Compared with the control group, the concentration of syndecan-1 and TNF-α was decreased in the ulinastatin group at T1, T2, and T3 (P<0.05). Compared with T0, OI was lower and PA-aO2 was higher at T2 and T3 in both groups, but the 2 indexes were improved in the ulinastatin group compared with those in the control group (P<0.05).
Conclusion: Ulinastatin can improve the post-operative pulmonary ventilation function in patients with mitral valve replacement. The mechanism may be associated with the inhibition of TNF-α release and the reduction of glycocalyx shedding induced by ulinastatin.
Cardiopulmonary Bypass
;
Glycocalyx
;
drug effects
;
Glycoproteins
;
pharmacology
;
Heart Valve Prosthesis Implantation
;
Humans
;
Lung
;
drug effects
;
Mitral Valve
;
surgery
;
Oxygen
;
blood
;
Syndecan-1
;
blood
;
Time Factors
;
Tumor Necrosis Factor-alpha
;
blood
2.Dexamethasone protects the glycocalyx on the kidney microvascular endothelium during severe acute pancreatitis.
Wen-Qiao YU ; Shao-Yang ZHANG ; Shui-Qiao FU ; Qing-Hui FU ; Wei-Na LU ; Jian ZHANG ; Zhong-Yan LIANG ; Yun ZHANG ; Ting-Bo LIANG
Journal of Zhejiang University. Science. B 2019;20(4):355-362
OBJECTIVE:
This study demonstrated that dexamethasone (DEX) protects the endothelial glycocalyx from damage induced by the inflammatory stimulus tumor necrosis factor-α (TNF-α) during severe acute pancreatitis (SAP), and improves the renal microcirculation.
METHODS:
Ninety mice were evenly divided into 3 groups (Sham, SAP, and SAP+DEX). The SAP mice model was established by ligature of pancreatic duct and intraperitoneal injection of cerulein. Renal perfusion and function, and morphological changes of the glycocalyx were evaluated by laser Doppler velocimetry, electron microscopy, and histopathology (hematoxylin and eosin (H&E) staining), respectively. Serum levels of syndecan-1 and TNF-α were assessed by enzyme-linked immunosorbent assay (ELISA). The protective effects of dexamethasone on the glycocalyx and renal microcirculation were evaluated.
RESULTS:
Significantly high levels of serum TNF-α were detected 3 h after the onset of SAP. These levels might induce degradation of the glycocalyx and kidney hypoperfusion, resulting in kidney microcirculation dysfunction. The application of dexamethasone reduced the degradation of the glycocalyx and improved perfusion of kidney.
CONCLUSIONS
Dexamethasone protects the endothelial glycocalyx from inflammatory degradation possibly initiated by TNF-α during SAP. This is might be a significant discovery that helps to prevent tissue edema and hypoperfusion in the future.
Acute Disease
;
Animals
;
Dexamethasone/pharmacology*
;
Disease Models, Animal
;
Edema/metabolism*
;
Endothelium, Vascular/metabolism*
;
Enzyme-Linked Immunosorbent Assay
;
Glycocalyx/drug effects*
;
Kidney/drug effects*
;
Male
;
Mice
;
Mice, Inbred C57BL
;
Microcirculation
;
Pancreatitis/drug therapy*
;
Perfusion
;
Protective Agents/pharmacology*
;
Tumor Necrosis Factor-alpha/metabolism*